Cefpodoxime 50mg with Sterile Water
Cefpodoxime 50mg/5mL dry syrup — same mechanism as PODROCK™ 25 (third-generation cephalosporin prodrug, PBP binding, cell wall synthesis inhibition, MSSA coverage). Calibrated for children approximately 8–20 kg (1–4 years) where the 25mg drops concentration requires impractically large volumes.
Acute otitis media, pharyngitis, tonsillitis, sinusitis, community-acquired pneumonia, UTI, and MSSA skin infections in children 1–4 years (8–20 kg). Superior to cefixime for infections with possible staphylococcal involvement.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
PODROCK™ 50 is the highest-volume paediatric cefpodoxime formulation — the 1–4 year age group represents the peak period for acute otitis media, pharyngitis, and community-acquired pneumonia prescribing. Its extended staphylococcal cover versus cefixime justifies its position as a step-up option for cases with suspected MSSA involvement or prior cefixime treatment failures.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.